###begin article-title 0
###xml 75 79 <span type="species:ncbi:10090">Mice</span>
Protective Role of Programmed Death 1 Ligand 1 (PD-L1)in Nonobese Diabetic Mice 
###end article-title 0
###begin p 1
###xml 39 60 39 60 <email xmlns:xlink="http://www.w3.org/1999/xlink">sytwu@ndmctsgh.edu.tw</email>
Corresponding author: Huey-Kang Sytwu, sytwu@ndmctsgh.edu.tw
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE</bold>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
OBJECTIVE-Coinhibitory signals mediated via programmed death 1 (PD-1) receptor play a critical role in downregulating immune responses and in maintaining peripheral tolerance. Programmed death 1 ligand 1 (PD-L1), the interacting ligand for PD-1, widely expressed in many cell types, acts as a tissue-specific negative regulator of pathogenic T-cell responses. We investigated the protective potential of PD-L1 on autoimmune diabetes by transgenically overexpressing PD-L1 in pancreatic beta-cells in nonobese diabetic (NOD) mice.
###end p 3
###begin p 4
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS</bold>
###xml 70 76 <span type="species:ncbi:10090">murine</span>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 405 420 <span type="species:ncbi:10090">transgenic mice</span>
RESEARCH DESIGN AND METHODS-We established an insulin promoter-driven murine PD-L1 transgenic NOD mouse model to directly evaluate the protective effect of an organ-specific PD-L1 transgene against autoimmune diabetes. Transgene expression, insulitis, and diabetic incidence were characterized in these transgenic NOD mice. Lymphocyte development, Th1 cells, and regulatory T-cells were analyzed in these transgenic mice; and T-cell proliferation, adoptive transfer, and islet transplantation were performed to evaluate the PD-L1 transgene-mediated immune-protective mechanisms.
###end p 4
###begin p 5
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS</bold>
###xml 43 58 <span type="species:ncbi:10090">transgenic mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 245 260 <span type="species:ncbi:10090">transgenic mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 415 430 <span type="species:ncbi:10090">transgenic mice</span>
RESULTS-The severity of insulitis in these transgenic mice is significantly decreased, disease onset is delayed, and the incidence of diabetes is markedly decreased compared with littermate controls. NOD/SCID mice that received lymphocytes from transgenic mice became diabetic at a slower rate than mice receiving control lymphocytes. Moreover, lymphocytes collected from recipients transferred by lymphocytes from transgenic mice revealed less proliferative potential than lymphocytes obtained from control recipients. Transgenic islets transplanted in diabetic recipients survived moderately longer than control islets.
###end p 5
###begin p 6
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS</bold>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
CONCLUSIONS-Our results demonstrate the protective potential of transgenic PD-L1 in autoimmune diabetes and illustrate its role in downregulating diabetogenic T-cells in NOD mice.
###end p 6
###begin p 7
Published ahead of print at  on 16 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 590 593 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
Programmed death 1 (PD-1) is an immunoreceptor of the CD28/CTLA-4 family whose expression is induced in activated T- and B-cells and in macrophages (1,2). PD-1 has two cytoplasmic tyrosine motifs: one an immunoreceptor tyrosine-based inhibition motif and the other an immunoreceptor tyrosine-based switch motif (ITSM). On interaction of PD-1 with its ligands PD-L1 (B7-H1) or PD-L2 (B7-DC), the tyrosine-phosphorylated ITSM of PD-1 recruits a src homology 2 domain-containing tyrosine phosphatase 2, which mediates the dephosphorylation signaling and reduces lymphocyte activation (3). PD-1-/- mice on different genetic backgrounds develop distinct autoimmune phenotypes, such as lupus-like glomerulonephritis/arthritis in C57Bl/6 (B6) mice or anticardiac troponin I-mediated dilated cardiomyopathy in Balb/c mice (4,5). These observations indicate that PD-1 is a critical negative regulator of lymphocyte activation and that the phenotype of PD-1 deficiency-induced autoimmunity is highly influenced by other genetic factors.
###end p 9
###begin p 10
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 679 682 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 732 735 732 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 742 743 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 768 771 768 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 904 905 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 1052 1056 <span type="species:ncbi:10090">mice</span>
###xml 1475 1479 <span type="species:ncbi:10090">mice</span>
Murine PD-L1 is expressed on many cell types, including stromal cells within many organs, but PD-L2 expression is much more restricted, occurring mainly in dendritic cells, activated monocytes, and macrophages (6,7). Although accumulating data indicate that both PD-L1/PD-1 and PD-L2/PD-1 signals can suppress T-cell proliferation and effector function by blocking cell cycle progression and cytokine production, signaling through PD-L1 interaction is more potent than that through PD-L2 (8). This is consistent with the observations that cytokine production, cytotoxic activity, and clonal expansion were significantly enhanced in T-cells and antigen-presenting cells from PD-L1-/- mice, compared with cells from wild-type or PD-L2-/- mice (9,10). Moreover, the PD-L1-/- mice revealed an increased susceptibility to the induction of autoimmune diseases, such as experimental allergic encephalomyelitis (9), strongly suggesting a protective role of tissue PD-L1 in the maintenance of immune tolerance. Furthermore, treatment of nonobese diabetic (NOD) mice with a combination of agonistic PD-L1.Ig fusion protein and monoclonal antibodies (mAbs) to CD154 induced long-term islet allograft survival, whereas the inhibition of PD-L1-mediated signals by blocking antibody exacerbated autoimmune diabetes (11). Based on these findings, we hypothesize that transgenic expression of PD-L1 in an islet-specific manner may help in preventing T-cell-mediated islet destruction in NOD mice.
###end p 10
###begin p 11
###xml 365 367 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
To investigate the preventive and/or therapeutic potential of PD-L1 in autoimmune diabetes, we generated transgenic NOD mice overexpressing PD-L1 under control of an insulin promoter. Although a recent report demonstrated that local expression of transgenic PD-L1 on beta-cells of B6 mice unexpectedly promotes organ-specific autoimmunity and transplant rejection (12), we hypothesized that overexpression of PD-L1 on islet cells in NOD mice would enhance inhibitory signaling through the PD-1-PD-L1 interaction and protect islet cells from lymphocyte attack. Our results demonstrate that transgenic PD-L1 on islet cells significantly ameliorates the severity of insulitis and incidence of diabetes in NOD mice. Interestingly, our results also indicate that local transgene expression not only protects islets in situ but also mediates a peripheral tolerance. Moreover, transgenic islets transplanted in diabetic recipients survived moderately longer than control islets. Overall, we demonstrate for the first time the preventive potential of transgenic PD-L1 in autoimmune diabetes and provide a theoretical basis for organ-specific genetic manipulation for disease prevention.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin p 13
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
NOD and NOD/SCID mice were purchased from The Jackson Laboratories (Bar Harbor, ME), and all mice were subsequently bred at the animal center of the National Defense Medical Center (Taipei, Taiwan, Republic of China) under specific pathogen-free conditions. The spontaneous incidence of diabetes in the colony was 80-90% in females and 20-30% in males by 25 weeks of age.
###end p 13
###begin title 14
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Generation of PD-L1 transgenic NOD mice.
###end title 14
###begin p 15
###xml 404 407 404 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 464 479 <span type="species:ncbi:10090">transgenic mice</span>
###xml 497 502 <span type="species:ncbi:9606">human</span>
###xml 594 600 <span type="species:ncbi:10090">murine</span>
###xml 721 726 <span type="species:ncbi:9606">human</span>
###xml 1001 1016 <span type="species:ncbi:10090">transgenic mice</span>
The PD-L1 gene was cloned from a cDNA library of mouse heart prepared with TRIzol and Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA). It was amplified by PCR with the forward primer 5'-TAGTTCCCAAAACATGAGGATA-3' and reverse primer 5'-AGAGGGTTCAACACTGCTTAC-3'. The PCR products were cloned into the pCR3.1 vector (Invitrogen) and subsequently sequenced. The pCR3.1-PD-L1 was digested with EcoRI and subcloned into pINS plasmid for the generation of transgenic mice (13). A modified human insulin promoter (pINS) was provided by Dr. Miyazaki (Osaka University, Osaka, Japan). The murine PD-L1 cDNA was inserted into the pINS plasmid to generate a pINS-mPD-L1 construct. The linearized DNA fragment with the human insulin promoter and PD-L1 cDNA was purified and microinjected into the pronuclei of NOD embryos at the one-cell stage and then implanted into pseudopregnant (BALB/c x FVB) F1 females. Southern blotting was performed to confirm the presence of the pINS-PD-L1 transgene. All transgenic mice used in our study were heterozygous for the PD-L1 transgene.
###end p 15
###begin title 16
Immunohistochemical analysis.
###end title 16
###begin p 17
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 157 160 <span type="species:ncbi:10116">rat</span>
###xml 166 171 <span type="species:ncbi:10090">mouse</span>
###xml 208 212 <span type="species:ncbi:9925">goat</span>
###xml 218 221 <span type="species:ncbi:10116">rat</span>
###xml 222 233 <span type="species:ncbi:3704">horseradish</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
The pancreas was removed from each mouse, embedded into Tissue-Tek O.C.T. compound, and fixed by acetone. Frozen sections of each sample were incubated with rat anti-mouse PD-L1 mAb (eBioscience) followed by goat anti-rat-horseradish peroxidase (HRP), and then stained with aminoethyl-carbazole reagent (DAKO, Carpinteria, CA) for 10 min. A fluorescent image was collected directly after treatment with phycoerythrin-conjugated anti-mouse PD-L1 mAb, and DAPI was used for background staining.
###end p 17
###begin title 18
Assessment of insulitis and diabetes.
###end title 18
###begin p 19
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
The severity of insulitis was scored on hematoxylin-eosin-stained sections of pancreas from mice 14-16 weeks of age by investigators blinded to the identity of the sections. At least 50 islets from each pancreas were randomly chosen for microscopic examination. The severity of insulitis was classified as described previously (14). Urine glucose concentration (glycosuria) was measured weekly or every other day using Chemstrips (Boehringer Mannheim, Indianapolis, IN). Animals scoring positive (>250 mg/dl glucose) on two consecutive tests were classified as diabetic.
###end p 19
###begin title 20
T-cell proliferation and division assay.
###end title 20
###begin p 21
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 301 302 301 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 265 270 <span type="species:ncbi:10090">mouse</span>
###xml 292 297 <span type="species:ncbi:9606">human</span>
Splenocytes from 8-week-old mice were treated with Tris-buffered ammonium chloride to eliminate the erythrocytes, washed, and resuspended at a concentration of 5 x 106 cells/ml in RPMI 1640. Cells were stimulated with immobilized anti-CD3 antibody (BD Pharmingen), mouse PD-L1.Ig, or control human IgG1.Ig (R&D Systems). The incorporation of [3H]methyl thymidine was detected at 72 h with a TopCount liquid scintillation counter (Packard). For assessment of cell division, splenocytes were labeled with 5 mumol/l carboxyfluorescein succinimidyl ester (CFSE) solution at room temperature for 5 min and washed three times in PBS containing 5% FBS by centrifugation at room temperature.
###end p 21
###begin title 22
Adoptive transfer.
###end title 22
###begin p 23
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 460 461 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
Splenocytes of female transgenic or nontransgenic NOD donors were treated with Tris-buffered ammonium chloride for erythrocyte depletion, and 2 x 107 cells were injected into female NOD/SCID mice via the retro-orbital plexus. Diabetes was assessed as described above. In another experiment using the procedure described above, 6-week-old female transgenic NOD mice or their nontransgenic control littermates were selected as recipients and injected with 2 x 107 cells from 12-week-old female NOD donors.
###end p 23
###begin title 24
Isolation of islet-infiltrated lymphocytes.
###end title 24
###begin p 25
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 342 347 <span type="species:ncbi:10090">mouse</span>
Pancreata were collected from 16- to 20-week-old transgenic or control NOD mice. Islets were isolated by collagenase digestion and Histopaque gradient purification. Marginal cells were collected and incubated with Cell Dissociation Buffer (Gibco). After passing over a cell strainer, suspended single cells were counted and stained with anti-mouse CD3 antibody for flow cytometric analysis. The percentage of infiltrated CD3+ cells in islets was obtained by gating on lymphocytes.
###end p 25
###begin title 26
Flow cytometry.
###end title 26
###begin p 27
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 139 144 <span type="species:ncbi:10090">mouse</span>
###xml 177 182 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:10090">mouse</span>
###xml 338 343 <span type="species:ncbi:10090">mouse</span>
Lymphocytes from spleen or pancreatic lymph node (PLN) were stained with anti-mouse CD4, CD8alpha, CD19, CD25, Foxp3 (BD Pharmingen), anti-mouse PD-1, PD-L1 (eBioscience), anti-human CD90 (hThy1, clone 5E10), and anti-mouse CD90.1 (mThy1.1, clone OX-7) (BD Pharmingen). CFSE-labeled lymphocytes were analyzed by triple staining with anti-mouse CD4 and CD8alpha antibodies. Flow cytometric analysis was performed with a FACSCalibur (BD Biosciences, San Diego, CA).
###end p 27
###begin title 28
Islet transplantation.
###end title 28
###begin p 29
###xml 22 37 <span type="species:ncbi:10090">transgenic mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
Regular NOD and PD-L1 transgenic mice at 6-8 weeks of age were used as donors for islet transplants. Newly diabetic female NOD mice with blood glucose concentrations between 300 and 500 mg/dl were collected as recipients. Islets were isolated by collagenase digestion and Histopaque gradient purification. Marginal islets with diameters between 20 and 75 mum were handpicked, and a total of 700 islets were implanted to the left renal capsule of recipient mice. Blood glucose concentrations of recipients were monitored daily. Loss of graft function was defined as a blood glucose result of >300 mg/dl in two consecutive evaluations.
###end p 29
###begin title 30
RESULTS
###end title 30
###begin title 31
Expression of PD-1 and the inhibitory effect of PD-L1 on NOD T-cells.
###end title 31
###begin p 32
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 534 541 534 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 649 650 649 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 706 707 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 739 744 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 857 858 857 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 862 863 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 979 980 979 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1076 1077 1076 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
To investigate the interactive role of PD-1 and PD-L1 in the regulation of autoimmune diabetes in NOD mice, we first determined the expression of PD-1 on NOD lymphocytes and evaluated the inhibitory potential of PD-L1. Our results indicated that <1% of splenocytes freshly isolated from 8-week-old female NOD or BALB/c mice expressed PD-1 (data not shown), suggesting a very low PD-1 expression on resting splenocytes in both strains. However, 48 h after anti-CD3 stimulation, the percentage of PD-1+ splenocytes increased to 50.34% (Fig. 1A, left), consistent with previous reports that PD-1 is upregulated after T-cell receptor (TCR) stimulation (1,15), and 72 h after stimulation, the percentage of PD-1+ cells reached 65.90% (Fig. 1A, right), suggesting an increase of PD-1 dependence on activation status. Interestingly, the increase in numbers of PD-1+ CD4+ T-cells (37.81 and 41.29% at 48 and 72 h, respectively) after stimulation is much less significant than that of CD8+ T-cells (84.58 and 92.16% at 48 and 72 h, respectively), suggesting a relative inability of CD4+ T-cells to induce PD-1 on activation.
###end p 32
###begin p 33
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 333 340 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
To investigate whether ligand binding to PD-1 can downregulate the activation status of NOD lymphocytes, we coated recombinant PD-L1.Ig on culture plates and measured the proliferation level of anti-CD3-stimulated lymphocytes. Our results clearly indicate a dose-dependent inhibition of proliferation of NOD lymphocytes by PD-L1.Ig (Fig. 1B), and they support the hypothesis that additional PD-1 signaling provided by coated PD-L1 can effectively downregulate NOD lymphocyte activation and proliferation. Therefore, we generated PD-L1 transgenic NOD mice and investigated whether beta-cell-specific transgene expression could mediate protection in autoimmune diabetes.
###end p 33
###begin title 34
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Generation of PD-L1 transgenic NOD mice.
###end title 34
###begin p 35
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 315 322 315 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 346 357 346 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-globin</italic>
###xml 365 370 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 409 413 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 414 420 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">globin</italic>
###xml 428 429 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 422 429 416 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 533 535 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 536 538 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 720 727 711 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 792 797 783 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 929 934 920 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 949 950 940 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 943 950 934 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1164 1165 1152 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1158 1165 1146 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1193 1194 1181 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1187 1194 1175 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 1292 1293 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1286 1293 1274 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1364 1365 1352 1353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1409 1410 1397 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1403 1410 1391 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 151 157 <span type="species:ncbi:10090">murine</span>
###xml 193 198 <span type="species:ncbi:10090">mouse</span>
###xml 339 345 <span type="species:ncbi:9986">rabbit</span>
###xml 359 364 <span type="species:ncbi:10090">mouse</span>
###xml 402 408 <span type="species:ncbi:9986">rabbit</span>
###xml 1630 1645 <span type="species:ncbi:10090">transgenic mice</span>
To directly evaluate the protective effect of an organ-specific PD-L1 transgene against autoimmune diabetes, we established an insulin promoter-driven murine PD-L1 (pINS-mPD-L1) transgenic NOD mouse model. The pINS-mPD-L1 construct contains the insulin promoter, the first and part of the second noncoding exons of insulin, an intron from rabbit beta-globin, mouse PD-L1 cDNA, and a poly-A signal from rabbit beta-globin (Fig. 2A). The insulin promoter is highly specific to beta-cells and leads to significant transgene production (13,16). To specifically determine the level of transcription of the PD-L1 transgene and to distinguish it from endogenous PD-L1, we designed a P1 primer to bind to the second exon of the insulin gene and a P3 primer to bind the 3' end of the coding region of PD-L1. The total expression of endogenous and transgenic PD-L1 was detected by a P2 primer binding to the 5' end of the coding region of PD-L1 and P3 (Fig. 2A). To test potential expression of pINS-mPDL1 transgene in NOD beta-cells, we transfected this construct into the NIT-1 cell line, an NOD insulinoma, and detected its expression by immunocytochemistry (ICC) (Fig. 2B) and flow cytometry (Fig. 2C). NIT-1 cells transfected with pINS-mPD-L1 revealed a strong PD-L1 signal detected by ICC (Fig. 2B), consistent with the flow cytometric data that 88% of cells are PD-L1+ compared with 7.6% of control cells (Fig. 2C). These results clearly demonstrate the expressional availability and feasibility of pINS-mPDL1 construct in NOD beta-cells. We therefore microinjected this construct into fertilized NOD eggs to generate the pINS-mPDL1 transgenic mice.
###end p 35
###begin p 36
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 160 167 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 375 376 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 369 376 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 417 424 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 653 660 653 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1016 1017 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1010 1017 1010 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1019 1022 1019 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1049 1056 1049 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1058 1064 1058 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 1114 1115 1114 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1108 1115 1108 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1117 1122 1117 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 1138 1139 1138 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1132 1139 1132 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1141 1145 1141 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 1280 1281 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1274 1281 1274 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1283 1309 1283 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right side of middle panel</italic>
###xml 1397 1398 1397 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1391 1398 1391 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1400 1425 1400 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left side of middle panel</italic>
###xml 1457 1458 1457 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1451 1458 1451 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 1625 1626 1625 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1619 1626 1619 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1628 1634 1628 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1147 1151 <span type="species:ncbi:10090">mice</span>
###xml 1318 1322 <span type="species:ncbi:10090">mice</span>
###xml 1512 1516 <span type="species:ncbi:10090">mice</span>
###xml 1613 1617 <span type="species:ncbi:10090">mice</span>
###xml 1688 1692 <span type="species:ncbi:10090">mice</span>
One of the transgenic lines obtained, denoted as L1C, was characterized. Southern blot analysis revealed one to five copies of the transgene in the L1C genome (Fig. 3A). The expression of transgenic PD-L1 was detected by RT-PCR with transgene-specific P1 and P3 primers. Our results demonstrate that transgenic PD-L1 was specifically expressed in pancreas in L1C mice (Fig. 3B), indicating the high stringency of the insulin promoter. Our results also indicate that in normal NOD mice, endogenous PD-L1 detected by P2 and P3 primers is highly expressed in several organs including thymus, heart, and spleen, but that the signal is very low in pancreas (Fig. 3B). High expression of PD-L1 in lymphoid organs suggests a critical role of PD-L1 in the induction and maintenance of immune tolerance, consistent with previous reports of the autoimmune phenotypes developed in PD-L1 knockout mice (9). To evaluate the expression of transgenic or endogenous PD-L1 at the protein level, we performed immunofluorescent (Fig. 3C, top) and immunohistochemical (Fig. 3C, middle) analyses on pancreatic sections from L1C (Fig. 3C, right) or NOD (Fig. 3C, left) mice. The results confirm that, consistent with the RT-PCR results, transgenic PD-L1 is highly expressed on pancreatic islets (Fig. 3C, right side of middle panel) in L1C mice, whereas the pancreatic expression of endogenous PD-L1 is very low (Fig. 3C, left side of middle panel) in control littermates (Fig. 3B). Expression patterns of insulin between L1C and NOD mice are very similar, suggesting that transgenic PD-L1 does not alter the insulin expression in L1C mice (Fig. 3C, bottom). Thus, we successfully generated L1C transgenic NOD mice in which the transgenic PD-L1 is overexpressed in an islet-specific manner.
###end p 36
###begin title 37
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Characterization of the diabetogenic process in L1C mice.
###end title 37
###begin p 38
###xml 388 389 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 382 389 382 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 485 486 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 887 888 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 903 904 903 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 897 904 897 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1465 1466 1465 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1459 1466 1459 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1580 1581 1580 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1978 1979 1978 1979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 2168 2169 2168 2169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2162 2169 2162 2169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 1039 1043 <span type="species:ncbi:10090">mice</span>
###xml 1148 1153 <span type="species:ncbi:10090">mouse</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1335 1339 <span type="species:ncbi:10090">mice</span>
###xml 1388 1392 <span type="species:ncbi:10090">mice</span>
###xml 1438 1442 <span type="species:ncbi:10090">mice</span>
###xml 1574 1578 <span type="species:ncbi:10090">mice</span>
###xml 1646 1650 <span type="species:ncbi:10090">mice</span>
###xml 1862 1866 <span type="species:ncbi:10090">mice</span>
###xml 1934 1938 <span type="species:ncbi:10090">mice</span>
###xml 2029 2033 <span type="species:ncbi:10090">mice</span>
###xml 2057 2061 <span type="species:ncbi:10090">mice</span>
###xml 2299 2303 <span type="species:ncbi:10090">mice</span>
To investigate the protective effects of organ-specific and membrane-bound expression of transgenic PD-L1 in autoimmune diabetes, we analyzed the severity of insulitis and the incidence of spontaneous diabetes in L1C mice. Although expression of the transgene did not completely prevent the development of insulitis, the severity of insulitis in L1C mice was significantly reduced (Fig. 4A). Around 50% of islets from L1C mice were free from lymphocytes compared with 20% in controls (P < 0.05); and only 5% islets from L1C showed destructive insulitis compared with 20% in controls (P < 0.05). In addition to histological analysis of insulitis, we further assessed the lymphocyte composition of the infiltrates within the islet by flow cytometry. Our result indicates that the percentage of CD3 T-cells in L1C islets is significantly decreased compared with control islets (26 vs. 36%, P < 0.05; Fig. 4B). To further investigate the protective efficacy of transgenic PD-L1, we analyzed spontaneous and lymphocyte transfer diabetes in L1C mice. Compared with control littermates, which started to develop diabetes at 11 weeks of age, the first L1C mouse became diabetic after 14 weeks, indicating a delay in onset of disease. At around 20 weeks of age, the diabetic incidence of control mice increased to 64%, but the incidence in L1C mice was only 10.8%. After 25 weeks, >88% of control mice developed diabetes, but the incidence in L1C mice was only 21.6% (Fig. 4C), demonstrating that transgenic PD-L1 significantly inhibits the development of autoimmune diabetes in NOD mice (P < 0.01). Because it is possible that the protection seen in L1C mice is due to modulation of the development of autoreactive T-cells by transgenic expression of PD-L1, we performed adoptive transfer experiments to further investigate whether PD-L1 overexpression can also protect mice from lymphocyte transfer-induced diabetes. Six-week-old female L1C mice were injected intravenously with 2 x 107 splenocytes isolated from 12-week-old female NOD mice. Around 60% of control mice developed diabetes 60 days after transfer, but L1C recipients remained diabetes free until 80 days (Fig. 4D), suggesting that islet-specific expression of PD-L1 not only inhibits the development of spontaneous diabetes but also protects mice from pathogenic lymphocyte transfer-mediated diabetes.
###end p 38
###begin p 39
###xml 461 462 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 471 478 468 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
One of the most stringent ways to test whether overexpression of PD-L1 could protect beta-cells against immune attack is to examine whether transgenic islet grafts could reverse hyperglycemia in diabetic NOD mice. We isolated islets from L1C mice and transplanted them into kidney capsules of diabetic NOD recipients. Although transgenic islets survived longer than wild-type islets, the result is not statistically significant (7.9 and 6.1 days, respectively, P = 0.06; Table 1), suggesting that expression of transgenic PD-L1 was partially effective in prolonging islet graft survival but did not provide complete protection from diabetes recurrence.
###end p 39
###begin title 40
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Lymphocyte development and the antidiabetogenic mechanism in L1C mice.
###end title 40
###begin p 41
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Thy1</italic>
###xml 507 516 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-&#947;</italic>
###xml 538 544 530 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Thy1.1</italic>
###xml 598 602 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-4</italic>
###xml 614 616 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 906 907 898 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 900 907 892 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 909 912 901 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 929 930 921 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 923 930 915 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 932 938 924 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 986 987 978 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 980 987 972 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1023 1024 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1017 1024 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1232 1233 1220 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1261 1262 1249 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 282 297 <span type="species:ncbi:10090">transgenic mice</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 371 386 <span type="species:ncbi:10090">transgenic mice</span>
###xml 405 420 <span type="species:ncbi:10090">transgenic mice</span>
###xml 442 447 <span type="species:ncbi:9606">human</span>
###xml 482 488 <span type="species:ncbi:10090">murine</span>
###xml 531 537 <span type="species:ncbi:10090">murine</span>
###xml 576 582 <span type="species:ncbi:10090">murine</span>
###xml 650 665 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1037 1052 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1161 1165 <span type="species:ncbi:10090">mice</span>
###xml 1309 1324 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1371 1386 <span type="species:ncbi:10090">transgenic mice</span>
It has been well characterized that an imbalance between Th1 and Th2 responses predisposes NOD mice to developing autoimmune diabetes (17). To investigate whether the protective effect of transgenic PD-L1 works through regulating Th1 and Th2 development in L1C mice, we crossed L1C transgenic mice with T1 and T2 double transgenic NOD mice to generate PD-L1/T1/T2 triple transgenic mice. T1 and T2 double transgenic mice bear two transgenes: human Thy1 (hThy1) under control of the murine interferon-gamma (IFN-gamma) promoter and murine Thy1.1 (mThy1.1) under control of the murine interleukin-4 (IL-4) promoter (18). Using these PD-L1/T1/T2 triple transgenic mice, we can directly measure the levels of Th1 and Th2 cells by detecting the expression of hThy1 (Th1 marker) and mThy1.1 (Th2 marker), respectively. The absolute cell numbers and distribution of each lymphocyte subpopulation in spleen (Fig. 5A, top) or PLNs (Fig. 5A, bottom) are similar between PD-L1/T1/T2 triple (Fig. 5A, gray bar) and T1/T2 double (Fig. 5A, black bar) transgenic mice, indicating that local expression of transgenic PD-L1 does not alter systemic lymphocyte development in NOD mice. Moreover, the number and percentage of IFN-gamma-producing (hThy1+) or IL-4-producing (mThy1.1+) cells in spleen or PLN in PD-L1/T1/T2 triple transgenic mice were not different from those in T1/T2 double transgenic mice, suggesting that transgenic PD-L1 in islets does not suppress systemic IFN-gamma-producing cells or induce IL-4-producing cells.
###end p 41
###begin p 42
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 351 352 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 400 401 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 394 401 394 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 436 443 436 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 445 448 445 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 498 499 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 525 532 525 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 555 556 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 549 556 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 367 382 <span type="species:ncbi:10090">transgenic mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
It has also been reported that NOD mice have a relative deficiency in CD4+25+ regulatory T-cells (Tregs), leading to an inability to maintain peripheral tolerance (19). To investigate whether transgenic PD-L1 can enhance the development of these Tregs and thus protect L1C mice from autoimmune diabetes, we analyzed the number and percentage of CD4+25+Foxp3 cells in transgenic mice. L1C mice (Fig. 5B, bottom) and control littermates (Fig. 5B, top) exhibited similar numbers and percentages of CD4+25+Foxp3 cells in spleen (Fig. 5B, left) and PLN (Fig. 5B, right), indicating that transgenic PD-L1 is not likely to increase the population of Tregs. These results also suggest that genetic manipulation of immune responses in an organ-specific manner is not likely to induce the systemic development of Tregs.
###end p 42
###begin p 43
###xml 787 788 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 781 788 781 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 1231 1232 1231 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1225 1232 1225 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 1416 1417 1416 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1410 1417 1410 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 1536 1537 1536 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1530 1537 1530 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
To further investigate the protective mechanism of transgenic PD-L1, we performed adoptive transfer experiments and functionally characterized the pathogenicity of T-cells in L1C mice. NOD/SCID recipients were injected intravenously with L1C or control splenocytes and the diabetic processes in the two groups were compared. In recipients of splenocytes from nontransgenic littermates, diabetes developed at 32 days after injection, whereas recipients of splenocytes from L1C mice developed disease at day 52. At day 60, all recipients of control cells had developed disease, whereas the disease incidence in recipients of L1C splenocytes was only 23.5%, although after this time, recipients of L1C splenocytes rapidly developed diabetes, and the incidence reached 90% at day 100 (Fig. 6A). These results indicate an impairment of L1C splenocytes in disease induction and suggest a potential role of transgenic PD-L1 in regulating autoimmunity in NOD mice. To further characterize the proliferation of L1C lymphocytes, we stimulated those cells with anti-CD3 or ConA. By CFSE-labeling experiments, we demonstrated that anti-CD3-stimulated L1C lymphocytes, both CD4 and CD8, divided much more slowly than control lymphocytes (Fig. 6B). Further analyses on lymphocytes isolated from NOD/SCID recipients also indicate that L1C lymphocytes were less proliferative and divided more slowly than control lymphocytes (Fig. 6C), consistent with the observation that L1C lymphocytes induced disease in recipients with a slower time course (Fig. 6A).
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1006 1007 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
PD-1 knockout mice in different genetic backgrounds develop various autoimmune diseases, not only indicating that negative costimulation via PD-1 is essential to downregulate inappropriate immune responses, such as autoimmunity and sustained inflammation, but also suggesting that PD-1 deficiency may exaggerate the genetic predisposition of autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, or lupus. PD-L1 acts as a tissue-specific negative regulator of pathogenic T-cell responses. Our result that PD-L1 is highly expressed in lymphoid organs, such as thymus, spleen, and lymph nodes, supports a critical role of PD-L1 in the induction and maintenance of immune tolerance, also consistent with previous reports of the autoimmune phenotypes developed in PD-L1 knockout mice (9). Moreover, the observation in our study that heart expresses high levels of PD-L1 may be linked to the abnormal phenotype in mice that develop fatal autoimmune cardiomyopathy due to a lack of PD-1 signaling (5).
###end p 45
###begin p 46
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 909 913 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-1</italic>
###xml 1061 1063 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1064 1066 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 91 94 <span type="species:ncbi:10116">rat</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
In contrast to our results in L1C mice, it has recently been reported that expression of a rat insulin promoter-driven PD-L1 transgene in mice on a B6 background unexpectedly enhanced T-cell priming and effector function and promoted autoimmunity (12). Based on the discrepancy between these two models, we propose that inhibitory regulation by PD-1/PD-L1 interactions may be highly dependent on the genetic background of mouse strains. This is supported by development of distinct autoimmune diseases in PD-1-deficient mice of different genetic backgrounds. NOD mice, unlike B6 mice, are well known for their potential for systemic autoimmunity and progressive pancreatic beta-cell-specific destruction. The genetic components involved in the regulation of PD-1 signaling and the eventual outcome of transgenic PD-L1 expression in beta-cells may differ between NOD and B6 mice. Although polymorphisms in the PD-1 gene may explain part of these complicated phenomena, the detailed mechanism for these strain-dependent variations of phenotype are not yet clear (20,21).
###end p 46
###begin p 47
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
###xml 1204 1219 <span type="species:ncbi:10090">transgenic mice</span>
PD-L1, in addition to binding to PD-1, has been reported to interact with a non-PD-1 receptor and to transmit both costimulatory and apoptotic signals (22). The PD-L1 binding sites for PD-1 and the unknown receptor are distinct. It has also been demonstrated that PD-L1 mutants with impaired PD-1 binding have significantly increased costimulatory potential (23). However, the regulation of the balance for PD-L1 transmitting a negative signal through PD-1 or a positive signal through the unknown receptor is not yet clear. The interactions of PD-L1 with PD-1 or the unknown receptor are distinct, and it is possible that they compete with each other to influence the TCR activation threshold (23). Therefore, it is possible that different threshold levels of regulation through the PD-1/PD-L1 or unknown receptor/PD-L1 pathways could lead to the divergent results in NOD and B6 mice. Finally, the differential levels of expression of transgenic and/or endogenous PD-L1 in beta-cells may also contribute to the discrepancy between these two models. It is possible that in L1C NOD mice, overexpressed transgenic PD-L1 binds PD-1 and transduces an inhibitory signal to autoreactive T-cells, whereas in B6 transgenic mice, overexpressed PD-L1 has a dominant-negative effect binding to PD-1 but, for some unknown reason, not transducing a signal.
###end p 47
###begin p 48
###xml 136 143 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
In our transplantation model, the failure of long-term graft survival may imply two possibilities. One possible explanation may be that insulin promoter-driving expression of PD-L1 was disturbed by the primary nonfunction of transplanted islets. Another possible explanation is that transplantation processes trigger strong oxidative stress- or cytokine-induced apoptosis of transplanted islets, which cannot be prevented by PD-L1.
###end p 48
###begin p 49
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 267 268 263 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 296 297 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 429 430 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 423 430 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 886 889 874 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 908 910 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1041 1044 1025 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1091 1092 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1093 1095 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1172 1175 1156 1159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1301 1304 1285 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 344 359 <span type="species:ncbi:10090">transgenic mice</span>
###xml 406 421 <span type="species:ncbi:10090">transgenic mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
###xml 1176 1180 <span type="species:ncbi:10090">mice</span>
###xml 1309 1313 <span type="species:ncbi:10090">mice</span>
It has been well characterized that an imbalance between Th1 and Th2 responses predisposes NOD mice to developing autoimmune diabetes (17). Based on our triple transgenic model in this study, we demonstrate that the number and percentage of IFN-gamma-producing (hThy1+) or IL-4-producing (mThy1.1+) cells in spleen or PLN in PD-L1/T1/T2 triple transgenic mice were not different from those in T1/T2 double transgenic mice (Fig. 5A), suggesting that transgenic PD-L1 in islets does not suppress systemic IFN-gamma-producing cells or induce IL-4-producing cells. This result does not support our original idea that the protective mechanism in L1C mice may be mediated by "rebalancing" Th1 and Th2 development. However, this result is consistent with the primary observation from another group that the numbers of IFN-gamma-or IL-4-producing cells in spleen and PLN are similar between PD1-/- and control mice (24). However, further analysis of T-cells infiltrating the pancreas revealed that the percentage of IFN-gamma-producing cells in PD-1-/- mice is much greater than in normal NOD mice (8,24). This considerable discrepancy in Th1 cell development between L1C and PD-1-/- mice suggests two possibilities. One possibility is that both PD-L1-and PD-L2-mediated signaling pathways are blocked in PD-1-/- NOD mice and this causes the net effect on Th1 polarization. Alternatively, whereas loss of function in PD-1 from a very early developmental stage substantially promotes the development of Th1 cells, a gain of function and local expression of transgenic PD-L1 insufficiently inhibits Th1 polarization and maintains the systemic Th1/Th2 balance.
###end p 49
###begin p 50
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 141 148 141 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Our result also revealed that L1C mice and control littermates exhibited similar numbers and percentages of CD4+25+ cells in spleen and PLN (Fig. 5A), suggesting that transgenic PD-L1 is not likely to increase the population of Tregs. This is supported by the data from L1C and from other transgenic lines generated in our laboratory in which the insulin promoter drives different immunomodulatory genes, including decoy receptor 3 (13), PD-L2, single-chain anti-CTLA-4 Fv, or heme oxygenase-1 (S. Shieh, S. Huang, H.-K.S., unpublished data), where our results suggest that "local" transgene-mediated protection is not through the induction of Tregs. These results also suggest that genetic manipulation of immune responses in an organ-specific manner is not likely to induce the systemic development of Tregs.
###end p 50
###begin p 51
###xml 128 131 128 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 520 523 520 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 590 591 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 770 774 <span type="species:ncbi:10090">mice</span>
The significant protection mediated by islet-specific PD-L1 expression in L1C mice is consistent with a recent report that PD-L1-/- NOD mice displayed an aggressive autoimmunity with a rapid onset of disease and complete diabetic penetrance (8). Consistent with these results, a current report also demonstrates that both the insulin-induced remission in new-onset autoimmune diabetes and the long-term maintenance of immune tolerance in NOD mice are highly dependent on the PD-1-PD-L1 pathway (25). Interestingly, PD-L2-/- mice developed a similar autoimmune phenotype to NOD littermates (8), consistent with our observation that transgenic expression of PD-L2 in islets mediates a weaker immunoprotection (C.-J.W., H.-K.S., unpublished data) than that observed in L1C mice. Both of these results support the uniqueness and importance of the role of PD-L1 in preventing autoimmune diabetes. A very recent report demonstrates that PD-L1 specifically interacting with the B7-1 costimulatory molecule suppresses T-cell responses and inhibits cytokine production (26). These bidirectional inhibitory interactions of PD-L1 to PD-1 and B7-1 provide an additional dimension to immune network of PD family and further support the preferential role of PD-L1 in mediating immunoprotection on autoimmune diseases.
###end p 51
###begin p 52
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 469 472 469 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 550 553 550 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
It has been reported that engagement of PD-1 and its ligand results in G0/G1 arrest and inhibits T-cell responses (7,27), and our study demonstrated that L1C lymphocytes were less responsive to TCR stimulation. This lymphocyte arrest may be caused by the interaction of PD-1 and transgenic PD-L1. PD-1/PD-L1-mediated inhibition can be overridden by various factors, such as CD28, IL-2, LPS, CpG, and IL-4 (28,29). The threshold of T-cell activation is decreased in PD-1-/- lymphocytes (30), consistent with the increased autoimmune reactivity in PD-1-/- mice (4,5). The results in our study suggest that local expression of transgenic PD-L1 in the pancreas of L1C mice, where autoantigens are highly expressed, inhibits the priming and clonal expansion of pathogenic lymphocytes at an early stage, suppressing the production of inflammatory factors and thus providing protection.
###end p 52
###begin p 53
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 589 604 <span type="species:ncbi:10090">transgenic mice</span>
Promoting an inhibitory signal through the PD-1/L1 pathway can also be applied as a therapeutic strategy in allograft transplantation. The ability of the PD-1/L1 pathway to negatively regulate alloimmunity and promote allograft survival has been demonstrated in various transplantation systems, including cardiac (29), skin (31), and islet transplantation (11). However, enhancing the PD-1 pathway alone is not enough to completely ensure graft survival, and combining treatment with cyclosporine A or CD154 blockade can more efficiently prevent graft rejection (11). Our results with L1C transgenic mice are the first demonstration of the protective potential of transgenic PD-L1 in autoimmune diabetes and provide a theoretical basis for genetic manipulation of islets for future transplantation.
###end p 53
###begin p 54
H.-K.S. has received grants NSC96-2628-B-016-002-MY3 and NSC96-3112-B-016-001 from the National Science Council (Taiwan, Republic of China). This work was supported in part by the C.Y. Foundation for Advancement of Education, Sciences, and Medicine.
###end p 54
###begin title 55
REFERENCES
###end title 55
###begin p 56
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 188 192 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 201 206 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 389 390 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 431 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 436 449 435 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom panels</italic>
###xml 518 519 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 679 680 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Expression of PD-1 and the inhibitory effect of PD-L1 on NOD T-cells. A: Splenocytes from 8-week-old female NOD mice were cultured in plates coated with 2 mug/ml anti-CD3 antibody for 48 (left) or 72 (right) hours. The stimulated cells were then stained with anti-PD-1 antibody (filled region), and the negative control of unstained cells is indicated as a dotted line. Percentages of PD-1+ cells in CD4 and CD8 populations (middle and bottom panels, respectively) are shown in the top right corner of the histograms. B: Splenocytes were cultured in plates coated with 2 mug/ml anti-CD3 antibody and 2.5 or 5 mug/ml PD-L1.Fc or control IgG1.Fc. Cells were pulsed with 5 muCi/ml [3H]thymidine at 60 h, and the incorporation was measured at 72 h by scintillation counting.
###end p 56
###begin p 57
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 270 277 270 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 431 438 431 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insulin</italic>
###xml 501 506 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 813 814 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 836 837 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 31 37 <span type="species:ncbi:10090">murine</span>
###xml 264 269 <span type="species:ncbi:9606">human</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
Construction and expression of murine PD-L1. A: Schematic diagram of the whole transgene construct. The black areas represent exons, and the gray areas represent introns. The entire first noncoding exon followed by the first intron and 16 bp of the second exon of human insulin gene, which are not translated into protein, were preserved to ensure the stringency of the insulin promoter. A forward primer in the second exon of the insulin gene (P1) and a backward primer in the coding region of mouse PD-L1 (P3) were designed to specifically evaluate PIns-mPD-L1 transcription. The total PD-L1 transcription can be detected by P2 and P3 primers. NIT-1 cells were transfected with PIns-mPD-L1 (right) or control plasmid (left). Cells were then stained by anti-PD-L1 antibody to detect the PD-L1 expression by ICC (B) and flow cytometry (C). Solid histogram indicates NIT-1 transfectants stained with anti-PD-L1 antibody, and dotted line indicates unstained transfectants.
###end p 57
###begin p 58
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PD-L1</italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 428 434 428 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 735 738 735 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 802 808 802 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">middle</italic>
###xml 827 833 827 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 874 880 874 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
Generation of PD-L1 transgenic NOD mice. A: Southern blot analysis identified the transgenic PD-L1 signal in one of the founders, denoted as L1C, and provided the relative copy number of the PD-L1 transgene in the L1C line. B: Islet-specific expression of the PD-L1 transgene was confirmed by RT-PCR analysis. The spliced transgenic PIns-mPD-L1 and endogenous PD-L1 transcripts from multiple organs of L1C (top) or regular NOD (bottom) mice were assessed. HGPRT transcription served as internal control. C: Frozen pancreatic sections of 6-week-old control NOD (left) or L1C (right) mice were stained with phycoerythrin-conjugated anti-PD-L1 antibody and then observed on a fluorescent microscope. DAPI was used as background staining (top). Immunohistochemical analysis was performed using anti-PD-L1 (middle) or anti-insulin (bottom) and HRP-conjugated secondary antibody (bottom)..
###end p 58
###begin p 59
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 323 324 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 467 468 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
Characterization of the diabetogenic process of PD-L1 transgenic mice. A: The insulitis scores were measured in seven mice of each group at 14-16 weeks old. B: The CD3 T-cells infiltrated in the pancreatic islets of L1C (black triangle) or control littermates (blacksquare, square, filled) were analyzed by flow cytometry. C: Spontaneous diabetes in female L1C (*, 37 mice) or their control littermates (o, 25 mice) was monitored by weekly measurement of glycosuria. D: The incidence of diabetes in L1C mice or control littermates adoptively transferred with splenocytes from 12-week-old female NOD mice was monitored by testing every other day for glycosuria.
###end p 59
###begin p 60
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 211 214 211 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 479 480 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 105 120 <span type="species:ncbi:10090">transgenic mice</span>
###xml 278 293 <span type="species:ncbi:10090">transgenic mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
Lymphocyte development and analyses of regulatory and helper T-cells in T1/T2 double or L1C/T1/T2 triple transgenic mice. A: The compositions of lymphocytes and the percentages of Th1, Th2, and Tregs in spleen (top) and PLN (bottom) from 8-week-old triple (gray bar) and double transgenic mice (black bar) were analyzed by flow cytometry. B: The population of Tregs of control (top) and L1C (bottom) mice was analyzed by the detection of CD25 and FoxP3 expression as gated on CD4+ lymphocytes in spleen (left) and PLN (right).
###end p 60
###begin p 61
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 446 447 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 623 627 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left</italic>
###xml 637 642 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 680 690 679 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right side</italic>
###xml 723 732 722 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">left side</italic>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
Adoptive transfer and lymphocyte division assay. A: The incidence of diabetes in NOD/SCID recipients adoptively transferred with splenocytes from 12- to 14-week-old L1C (*) or control (o) mice was assessed by testing for glycosuria every other day. B: Splenocytes from L1C (right) or control (left) mice were labeled with CFSE, stimulated in plates coated with 4 mug/ml anti-CD3 antibody, and analyzed by flow cytometry 3 days after stimulation. C: CFSE-labeled splenocytes from L1C or control mice were adoptively transferred into NOD/SCID mice to investigate their ability to divide in vivo. The lymphocytes from spleen (left) or PLN (right) of recipients transferred from L1C (right side of each panel) or control mice (left side of each panel) were analyzed by flow cytometry at day 3 after transfer. The mean fluorescence intensity was indicated on the bottom of each plot.
###end p 61
###begin p 62
Transgenic PD-L1 moderately prolongs the survival period of grafts in isogenic islet transplantation
###end p 62
###begin p 63
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Pancreatic islets isolated from 6- to 8-week-old mice were transplanted into recipients that were newly diagnosed with diabetes. Blood glucose concentration of recipients was monitored every day. The recurrence of diabetes among the recipients was defined as a recipient blood glucose concentration >16.7 mmol/l in two consecutive evaluations. The day of diabetic recurrence was considered as the end of islet survival.
###end p 63

